Back to search

Peptide record

TPDB07533

Antibacterial Antifungal Toxicity standard
14 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07533
Antibacterial Antifungal Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AFP-GFuse
standard
No
A 14-aa standard natural multi-activity (Antibacterial, Antifungal, and Toxicity) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KILGKLWKGVKSIF
Physicochemical Analysis
C80H133N19O16
ARNDCEQHMPTY
K
1617.05
11.00
4
0
7
+4
-0.54
0.393
132.14
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
340.12
1
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
2
I
2
L
4
K
0
M
1
F
0
P
1
S
0
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 2 L: 2 K: 4 M: 0 F: 1 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 1
Chemical Descriptors
14
C80H133N19O16
1617.05
11.00
+4
-0.54
0.393
Evidence Records 11 records
Evidence 1 Activity

Activity

MIC
Antibacterial
25-50 µg/mL

Target

Escherichia coli AB94012 or ATCC25922

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against Gram- E. coli AB94012 or ATCC25922 (MIC 25-50 ug/ml), P. aeruginosa AB93066 or ATCC9027 (MIC 50 ug/ml), Gram+ S. aureus AB94004 or ATCC25923 o
Evidence 2 Activity

Activity

MIC
Antibacterial
50 µg/mL

Target

Pseudomonas aeruginosa AB93066 or ATCC9027

Source & Reference

dbAMP DRAMP

Other

active against Gram- E. coli AB94012 or ATCC25922 (MIC 25-50 ug/ml), P. aeruginosa AB93066 or ATCC9027 (MIC 50 ug/ml), Gram+ S. aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374 (MIC 6.25-12.5 ug/ml).
Evidence 3 Activity

Activity

MIC
Antibacterial
6.25-12.5 µg/mL

Target

Staphylococcus aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374

Source & Reference

dbAMP DRAMP

Other

2 or ATCC25922 (MIC 25-50 ug/ml), P. aeruginosa AB93066 or ATCC9027 (MIC 50 ug/ml), Gram+ S. aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374 (MIC 6.25-12.5 ug/ml). Also active against C. albicans ATCC 10231 or CMCC 98001 or AY 93025 and 5 clinical stra
Evidence 4 Activity

Activity

MIC
Antibacterial
15.5-62 µM

Target

Candida albicans ATCC 10231 or CMCC 98001 or AY 93025 and 5 clinical strains

Source & Reference

dbAMP DRAMP

Other

94004 or ATCC25923 or MRSA P1381 or MRSA P1374 (MIC 6.25-12.5 ug/ml). Also active against C. albicans ATCC 10231 or CMCC 98001 or AY 93025 and 5 clinical strains (MIC 15.5-62 uM). inhibits C. albicans hyphal formation and formation of biofilms:Fungi:C. albicans at 50
Evidence 5 Activity

Activity

MIC
Antifungal
25-50 µg/mL

Target

Escherichia coli AB94012 or ATCC25922

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
active against Gram- E. coli AB94012 or ATCC25922 (MIC 25-50 ug/ml), P. aeruginosa AB93066 or ATCC9027 (MIC 50 ug/ml), Gram+ S. aureus AB94004 or ATCC25923 o
Evidence 6 Activity

Activity

MIC
Antifungal
50 µg/mL

Target

Pseudomonas aeruginosa AB93066 or ATCC9027

Source & Reference

dbAMP DRAMP

Other

active against Gram- E. coli AB94012 or ATCC25922 (MIC 25-50 ug/ml), P. aeruginosa AB93066 or ATCC9027 (MIC 50 ug/ml), Gram+ S. aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374 (MIC 6.25-12.5 ug/ml).
Evidence 7 Activity

Activity

MIC
Antifungal
6.25-12.5 µg/mL

Target

Staphylococcus aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374

Source & Reference

dbAMP DRAMP

Other

2 or ATCC25922 (MIC 25-50 ug/ml), P. aeruginosa AB93066 or ATCC9027 (MIC 50 ug/ml), Gram+ S. aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374 (MIC 6.25-12.5 ug/ml). Also active against C. albicans ATCC 10231 or CMCC 98001 or AY 93025 and 5 clinical stra
Evidence 8 Activity

Activity

MIC
Antifungal
15.5-62 µM

Target

Candida albicans ATCC 10231 or CMCC 98001 or AY 93025 and 5 clinical strains

Source & Reference

dbAMP DRAMP

Other

94004 or ATCC25923 or MRSA P1381 or MRSA P1374 (MIC 6.25-12.5 ug/ml). Also active against C. albicans ATCC 10231 or CMCC 98001 or AY 93025 and 5 clinical strains (MIC 15.5-62 uM). inhibits C. albicans hyphal formation and formation of biofilms:Fungi:C. albicans at 50
Evidence 9 Activity

Activity

0% Hemolysis
Toxicity
200 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 200 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
K1K8: an Hp1404-derived antibacterial peptide. | Appl Microbiol Biotechnol | 2016
Evidence 10 Activity

Activity

12% Hemolysis
Toxicity
400 µg/mL
Hemolytic Cytotoxic
12% Hemolysis | 400 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
K1K8: an Hp1404-derived antibacterial peptide. | Appl Microbiol Biotechnol | 2016
Evidence 11 Activity

Activity

% Hemolysis
Toxicity
10 %
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.26952110] 10% hemolysis at 400µg/mL against human red blood cells | Cytotoxicity: [Ref.26952110] The cell vaibility of HFF cell lines is 100%, 108%, 105% and 38% at peptide concentrations of 0 µg/ml, 50 µg/ml, 100 µg/ml and 200 µg/ml. ##The cell viability of HEK293T cell lines is 105%, 125%, 101% and 21% at peptide concentrations of

Target

erythrocytes

Source & Reference

NA
DRAMP
Appl Microbiol Biotechnol. 2016 Jun 100(11):5069-77.